GSK announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expansion of Arexvy, its respiratory syncytial virus (RSV) vaccine, to adults aged 18 and older. This recommendation marks a significant step forward in enhancing the availability of RSV prevention options for the broader adult population.
The final decision by the European Commission is anticipated in February 2026. If approved, this will allow Arexvy to be accessible to a wider audience, complementing its current approval for adults aged 60 and older, and those aged 50 to 59 who are at increased risk of severe RSV disease.
Sanjay Gurunathan, GSK’s head of vaccines and infectious diseases research and development, emphasized the importance of this positive opinion from the CHMP, stating, “Today’s positive CHMP opinion is an important step towards bringing more options to prevent severe RSV disease for adults in Europe.” He reaffirmed GSK’s commitment to increasing vaccine access and driving innovation to simplify protection efforts against RSV.
In response to this news, GSK shares experienced a modest increase of 0.14%, reaching 1,823.50 pence as of 0820 GMT. This reflects investor optimism regarding the potential expansion of the company’s vaccine portfolio and its impact on public health initiatives.
By prioritizing the development of vaccines and expanding their indications, GSK is contributing to a proactive approach in infectious disease prevention, which is crucial for enhancing health outcomes across Europe.